About me
Model informed drug discovery and development (MID3) supports effective, efficient, and rational decisions throughout the development timeline and across therapeutic areas. Some examples of the impact that my work (particularly pharmacokinetic pharmacodynamic (PKPD) modeling and simulation (M&S)) has had during my career as an industry pharmacometrician include: selection of the optimal dosing regimen for future trials and for the package insert; determination of the probability of efficacy and safety of a proposed dosing regimen; assessment of the feasibility of therapeutic drug monitoring in the clinic; optimization of study design; identification of explanatory covariates for pharmacokinetic anomalies and identification of responders/non responders; bridging between indications within a compound using common biomarkers and safety measures; scaling from animal to human, from healthy volunteers to patients, and from adults to pediatric patients.
As my career progressed from being an individual contributor in Pharma to a group leader, my passion and recognized expertise has moved towards strategic application of pharmacometrics tools and techniques; process/infrastructure development and implementation of standards and best practices for MID3; effective science communication; professional development employees through identification of opportunities for external leadership and internal mentoring; and training in the often forgotten but critically important soft skills.
These skills were instrumental in my position as VP Scientific Engagement at Metrum Research Group. I interfaced with potential clients to understand the clinical questions and key decisions that required a quantitative approach for support; using my science and strategic drug development background, I was able to “translate” the client needs into appropriate MIDD approaches for our
internal science team to apply. I also took a lead role in assisting clients with the evaluation of their current pharmacometrics processes, and recommending processes and tools that would fill the gaps and allow for more effective, efficient, and standardized pharmacometrics analyses.
I recently launched my own consulting business targeting the MIDD and Pharmacometrics community to help individuals, teams, and organizations become even more impactful through the development of leadership, communication, and change management skills.
